Calls for papers
-
Inhaled drug developer Aerami Therapeutics has announced that it will go public through a merger with a special purpose acquisition company (SPAC) called FoxWayne Enterprises Acquisition Corp., and the resulting company’s common stock will be… Read more . . .
-
The Cystic Fibrosis Foundation announced that it is providing $3.5 million for a Phase 2 study of Pulmocide Ltd’s PC945 inhaled opelconazole for the prevention of pulmonary Aspergillus infections following lung transplantation. The CF Foundation noted… Read more . . .
-
Biohaven Pharmaceutical said that a Phase 3 trial of its intranasal zavegepant (BHV-3500) for the treatment of moderate or severe migraine has met its primary endpoints, demonstrating statistically significant increase in freedom from both pain and… Read more . . .
-
Lupin announced that it has acquired exclusive global rights to soft mist inhalation technology developed by Cambridge, UK design company TTP, and the two companies will co-develop the SMI device for delivery of inhaled drugs.… Read more . . .
-
Inhaled nitric oxide developer Beyond Air announced that pulmonologist Andrew Colin has been appointed as the company’s Chief Medical Officer, effective December 1, 2021. Colin, who was most recently Chief of the Division of Pediatric… Read more . . .
-
Canadian pharma company Pharmascience has announced that it will stop manufacturing pms-sodium cromoglycate inhalation solution due to a 95% drop in demand over the past 15 years. Pharmascience now says it will sell pms-sodium cromoglycate… Read more . . .
-
By the ISAM board of directors As scientific leaders during a respiratory pandemic, the International Society for Aerosols in Medicine (ISAM) has been very busy over the past year, working to advance the understanding of… Read more . . .
-
Following the lifting of government restrictions related to the COVID-19 pandemic, device design and development company Team Consulting is once again welcoming visitors to its headquarters in Cambridge, UK. Team has recently opened a new… Read more . . .
-
The FDA has approved Alembic Pharmaceuticals’ ANDA for its formoterol fumarate inhalation solution, a generic of Mylan’s Perforomist inhalation solution for the treatment of COPD, the company said. According to the announcement, this is the… Read more . . .
-
Janssen Pharmaceutical announced that it has launched Spravato esketamine nasal spray in Australia for the treatment of treatment-resistant depression following approval by the TGA. The company also said that will file a submission to the… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK